Predicting bone scan findings using sPSA in patients newly diagnosed of prostate cancer: Feasibility in Asian population

Urologic Oncology: Seminars and Original Investigations

Volumn 29, Issue 3, 2011, Pages 275-279

  Lai, Miranda H Y ^a   Luk, Wing Hang ^a   Chan, James C S ^a  

^a UNITED CHRISTIAN HOSPITAL   (Hong Kong)

Author keywords

Bone metastases; Bone scintigraphy; Gleason score; Prostate cancer; Prostate specific antigen (PSA)

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; ASIAN; BONE METASTASIS; BONE SCINTISCANNING; CANCER RISK; CLINICAL ARTICLE; FEASIBILITY STUDY; GLEASON SCORE; HUMAN; INFORMATION PROCESSING; MEDICAL RECORD; MULTICENTER STUDY; POPULATION; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; BONE NEOPLASMS; FEASIBILITY STUDIES; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES;

EID: 79955713421     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.05.007     Document Type: Article

References (14)

1. Hong Kong Cancer Registry, Hospital Authority.
2. Risk factors for prostate cancer, family history, and genetic predisposition. National Cancer Institute, U.S. National Institute of Health: Bethesda, MD.
3. Meng E., Sun G.H., Wu S.T., et al. Value of prostate-specific antigen in the staging of Taiwanese patients with newly diagnosed prostate cancer. Arch Andrology 2003, 49:471-474.
4. Farkas A., Marcella S., Rhoads G. Ethnic and racial differences in prostate cancer incidence and mortality. Ethn Dis 2000, 10:69-75.
5. Koizumi M., Maeda H., Yoshimura K., et al. Dissociation of bone formation markers in bone metastasis of prostate cancer. Br J Cancer 1997, 75:1601-1604.
6. Kosuda S., Yoshimura I., Aizawa T., et al. Can initial prostate specific antigen determinations eliminate the need for bone scans in patients with newly diagnosed prostate carcinoma?. Cancer 2002, 94:964-972.
7. Lee N., Fawaaz R., Olsson C.A., et al. Which patients with newly diagnosed prostate cancer need a radionuclide bone scan?. An analysis based on 631 patients. Int J Radiat Oncol Biol Phys 2000, 48:1443-1446.
8. Oesterling J.E. Using PSA to eliminate the staging radionuclide bone scan: Significant economic implications. Urol Clin North Am 1993, 20:705-711.
9. Chybowski F.M., Larson Keller J.J., Bergstralh E.J., et al. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: Prostate-specific antigen is superior to all other clinical parameters. J Urol 1991, 145:313-318.
10. Oesterling J.E., Martin S.K., Bergstralh E.J., et al. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 1993, 269:57-60.
11. Gleave M.E., Coupland D., Drachenberg D., et al. Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer. Urology 1996, 47:708-712.
12. Lin K., Szabo Z., Chin B.B., et al. The value of a baseline bone scan in patients with newly diagnosed prostate cancer. Clin Nucl Med 1999, 24:579-582.
13. Ito K., Kubota Y., Suzuki K., et al. Correlation of prostate-specific antigen before prostate cancer detection and clinicopathologic features: Evaluation of mass screening populations. Urology 2000, 55:705-709.
14. Hoffman R.M., Stone S.N., Espey D., et al. Differences between men with screening-detected versus clinically diagnosed prostate cancers in the USA. BMC Cancer 2005, 5:27.